Clinical Trial Update: Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) [Phase 3]

View source ↗

Summary

Open-label Phase III trial of NABI-IGIV 10% in subjects with primary immune deficiency disorders has completed; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Deficiency Disorders

Drugs mentioned

• NABI-IGIV 10% (immune globulin intravenous (human), 10%)

Snippet

Sponsor: ADMA Biologics, Inc. | Conditions: Primary Immune Deficiency Disorders (PIDD) | Phase 3 | Status: COMPLETED | Results posted: 2012-03-26